Q1 2022 Results
Company overview
Financial performance
CRM
Immunology
Financial review
Neuroscience
2022 priorities
Innovation: Pipeline overview
Ophthalmology
Appendix
Innovation: Clinical trials
Respiratory & Allergy
Oncology: Solid Tumors
ianalumab - BAFF-R inhibitor
Study
Indication
Phase
Patients
Primary Outcome
Measures
NCT03217422 AMBER (CVAY736B2201)
Autoimmune hepatitis
Phase 2
80
Alanine aminotransferase (ALT) normalization
Arms Intervention
VAY736
Placebo control with conversion to active VAY736
Autoimmune hepatitis patients with incomplete response or intolerant to standard
treatment of care
Target Patients
Read-out Milestone(s)
2026
Publication
TBD
References
Abbreviations
Hematology
Biosimilars
Global Health
63 Investor Relations | Q1 2022 Results
1 NOVARTIS | Reimagining MedicineView entire presentation